A recent editorial by Barnett' stated: 'There is no evidence that patients or physicians are harmed by our present techniques as long as the techniques meet existing standards'. While this may have some elements of truth, it is important to recognize that there appears to be evidence that many of our existing standards have either deteriorated with time (or not continued to improve) perhaps due to either complacency or the possibly inferior performance of newer analytical system^.^^^ There are, however, other plausible reasons for this. In evaluations of reagent kit sets and instruments, desirable standards of performance are used rarely as criteria for a c~e p t a b i l i t y ;~.~ empirical comments such as 'the analytical performance is acceptable', 'it gave acceptable precision' and 'precision was excellent' are often used,6 which imply, without objectivity or good documentation, that the analytical performance achieved is satisfactory. Moreover, expansion of the use of instruments designed to be operated by relatively unskilled staff has occurred, even though many studies have shown that the standards of specimen collection technique and analytical performance are generally inferior to those obtained by skilled staff in laboratories. In addition, many have stated that the imprecision of analytical techniques is no longer a problem and that available resources should be directed to lowering inaccuracy and improving betweenlaboratory transferability of results. We fully support improvements in analytical methodology which reduce inaccuracy and non-specificity. However, analytical imprecision cannot be neglected. We believe that the current situation should be a matter of concern and that further improvement in analytical imprecision is warranted and of both clinical and laboratory importance. 1979; 72: 374-82 1 1 Hyltoft Petersen P, Larsen ML, Horder M, Blaabjerg 0. Influence of analytical quality and pre analytical variations on measurements of cholesterol in screening programmes. Scan J CIin Lab Invest 12 Harris EK. Statistical aspects of reference values in clinical pathology. Prog Clin Patholl981; 8: 45-66 13 Young DS. Why there is a laboratory. In: Young DS, Hicks J, Nipper H, Uddin D, eds. Clinician and Chemist. Washington: AACC, 1979: 3-22 14 Fraser CG, Hyltoft Petersen P, Larsen ML. Setting analytical goals for random analytical error in specific clinical monitoring situations. Clin Chem 1990; 36: 1625-8 15 Diemk, Lentner C, eds. Scientific Tables. 7th Ed. Bask: Ciba-Geigy, 1970: 28-9 16 Fraser CG, Browning MCK. Deciding the optimum interval between specimen collections: theory and nomograms. Clin Chem 1987; 33: 1436-8 17 Westgard JO, Burnett RW. Precision requirements for cost-effective operation of analytical processes. Clin Chem 1990; 36: 1629-32 18 Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989: 21: 409-37 1990; 50 (SUPPI 198): 66-72
TERMINOLOGY AND ASSUMPTIONS
In order to examine the effects of random types of error on clinical decision-making and laboratory management, we shall use the following terminology and abbreviations.
CV, is the between batch analytical imprecision, expressed as coefficient of variation (CV). Between batch imprecision is the relevant variable because various aspects of the use of laboratory test results in patient care are being examined. Moreover, it is assumed that imprecision, as C V , is a constant for each analyte in the individual laboratory and distributed in a Gaussian manner.
CV, is the pre-analytical variation, which includes variation in specimen collection technique, application of tourniquet, etc. Particularly in the setting of near-patient testing, when skilled phlebotomy teams are unlikely to be available, CV, and CV, will be integrated and the overall measurement variability,' CV, = (CVA2 + CVP2)", will be of concern. We shall only separate these variables when it is reasonable or logical to d o so. When CV, is negligible, C V , is the average pure biological withinsubject variation; the random fluctuation around an individual's own homeostatic set-point, expressed as C V .
CV, is the biological between-subject variation, the difference between the homeostatic setpoints of individuals, expressed as C V .
Here we shall assume that biological sources of pre-analytical variation, such as diurnal variation and previous intake of food are either minimal, or are an integral part of the C V , estimate.
There are many published data on C V , and CVG.8-9 Since the estimates are very similar in all published works, irrespective of number of subjects studied, time span of study, age of subjects, analytical methodology, country and state of health, we shall use the average of all studies of more than 1 week's duration on healthy subjects here for illustrative purposes. We shall cv, = c v , . use, as examples, analytes which are assayed in clinics and wards as well as in laboratories to better show the importance of measurement imprecision, since this is likely to be larger in such situations.
TEST RESULT VARIABILITY
The results of laboratory tests are generally reported as single numbers which are estimates of the homeostatic set-point and thus just one point in the interval around this. The interval encompasses measurement imprecision and withinsubject biological variation. The latter is assumed to be constant, as discussed above. The influence of measurement imprecision on true test result variability can be calculated, in percentage terms, as:
The effect is shown in Table 1 . When CV,/ CV, becomes greater than 1 -7 3 , then measurement imprecision has a greater influence on test result variability than intrinsic biological factors.
Such considerations played major roles in the development of the widely accepted proposal'" that desirable analytical imprecision should be calculated as:
where CV, is assumed to be zero.
If this is achieved, then ca 10% is added to test result variability through measurement imprecision.
DECISION LIMITS AND REFERENCE VALUES
Measurement imprecision affects the consequences of using fixed decision limits as criteria of risk.
For example, Hyltoft Petersen et at. I' have shown that, for cholesterol, a Danish population had a mean serum concentration of 5 . 4 mmol/L with a biological CV of 1.23 mmol/L. If persons with true concentrations of above 7 .O mmol/L are considered at high risk (10% of the distribution) then, if the analytical imprecision was CV, = lo%, the number of persons erroneously classified is 8% of the population. If CV, was greater than zero, the problem would be of greater significance.
More often, conventional population-based reference values are used to aid diagnosis; these are of utility only when the between-subject variation is smaller than the within-subject variation.I2 Otherwise, individuals might have values which would be highly unusual for them but would still lie within the reference limits. More formally, an index of individuality can be calculated as:
When this index is less than 0.6, reference values are of limited utility: they become useful when the index is more than 1.4.12
As an example, serum calcium has CV,= 1.8% and CV,=2.1%. The influence of measurement imprecision on the index of individuality is shown in Table 2 and it seems that population-based reference values become of greater utility as measurement imprecision increases. However, this is an invalid conclusion. In practice, large measurement imprecision means greater dispersion of the single diagnostic result; this has the consequence that values which are really inside (or outside) reference limits may lie outside (or inside) due to this variability and the test has decreased medical usefulness. It is clear that inaccuracy has other, and sometimes more serious effects, but these will not be discussed further here.
THE SIGNIFICANCE OF CHANGE
Most laboratory test results are used in monitoring patients rather than to aid in the diagnostic process.I3 The critical difference required for serial results to have significantly changed, in percentage terms, is:
where Z is the Z-score and represents the number of standard deviations equivalent to the probability chosen. The numerical value of Z also depends on whether the change is unidirectional (rise or fall) or bidire~tiona1.l~ Values for Z may be found in statistical tables such as Geigy.15
Thus, measurement imprecision has a profound effect on the critical difference. For example, for cholesterol, which has CV, = 6 % , the critical differences for Pg0.05 are shown in Table 3 at different levels of measurement imprecision.
Similarly, if a specific change in serial results is deemed to be the clinical criterion for action, then the measurement imprecision achieved affects the probability with which this decision can be made. Again using cholesterol as an example, the effect of measurement imprecision on the probability that a fall of 15% is significant is shown in Table 4 ; these probabilities can be simply calculated using a rearrangement of the above formula, namely: 1 .414.(CV,'+ CV,') and consulting the appropriate statistical tables to find the probability appropriate to the Z-score.
TABI.F 4. Probability that a fall in serum cholesterol concentration of 15% is significanf ut different levels of measurement imprecision

Imprecision (To)
Probability ( 
NUMBER OF SPECIMENS
Analysis in replicate reduces the variability of the estimate, because, if the mean of replicates is taken, its standard error [ SD/(n)"] becomes smaller as the number (n) of assays increases.
This fact is used in laboratory medicine since it is common to repeat equivocal results to obtain a better estimate of the true mean value.
The influence of measurement imprecision on this approach can be seen by consideration of the number of specimens required to be sure, with certain probability, that the mean value is within a stated percentage ( is within 5 % of the true value, varies with measurement imprecision is shown in Table 5 . It is also common practice t o 'confirm' results before taking clinical action. The above formula can be used to assess the effect of taking multiple specimens and performing analyses on each of them. For example, for cholesterol, for CV, = 3 % and C V , = 6 % , performing assays on two specimens from an individual means that, in addition to the 95% dispersion of the mean value falling from ? 1 3 . 1 Vo to ? 9.3%, the probability that the mean lies within ? 5 % of its true value rises from 54% to 7O%, easily calculated from: Z = p . H(CV,2+ CV,*)"
TIME BETWEEN SPECIMEN COLLECTION
Certain analytes of interest to the clinical chemist decay in a first-order manner. For these, the time which must be allowed to elapse before results obtained on specimens which are different can be said to have changed with a stated probability is where T is the time difference and t is the elimination half-life. For example, if lithium toxicity was being monitored, then, assuming a half-life of 58 h, the times which would have to elapse between collections of specimens before significant, PGO.05, falls in specimen concentration could be detected are related to measurement imprecision as shown in Table 6 . As mentioned above, probability can be calculated by simple rearrangement of the equation and substitution of the appropriate Z-score for the 2 -3 3 quoted. For example, if CV,= 1, 2 and 3% and specimens were taken at 2 h intervals, the probabilities that a fall could be said to be significant are 99, 89 and 79%, respectively.
MEASUREMENT IMPRECISION AND CONTROL OF QUALITY
Much experience exists in performing ongoing control of analytical quality in clinical chemistry. Traditionally, the quality of the analytical process is monitored by use of reference (control) samples which are assumed to have negligible inter-vial variability and good stability. In brief, the analytical imprecision, CV, (or as standard deviation, sA), is assumed as the measure of stable analytical performance and provides the basis for modern quality control systems.I7 The choice of control rules depends on the quality to be guaranteed, even during unstable performance when errors are present, by setting up criteria for rejection of analytical runs with errors of magnitude more than 'the maximum allowable error' or 'medical important error'. The control rules adopted play a major part in determining the probability of error detection, Ped, and the probability of false rejection, P,,.
The validity of any control system is highly dependent on CV, (s,). If, for example, the maximum allowable systematic error is 10%. then, with CV, = 5%, one control measurement, and a control rule of the type ,T? 2.s, ( 12J, the probability of detecting and rejecting a systematic error of ? 10% is Ped= 50%. Moreover, the probability of false rejection is P,, = 5%. If the CV, is reduced t o half (CV, = 2 -5 % ) , the same control rule (1,) would increase the Pd to 97.5% Alternatively, if the rule was changed to F ? 3 . s , (13s), the Ped would be 84% and P,, would be reduced to 0 . 3 % . Any reduction in CV, will improve the effectiveness of quality control systems. Furthermore, a low analytical imprecision makes monitoring of analytical inaccuracy easier, increases Pd for critical random errors, and lowers detection limit. In addition, the increase in Ped and decrease in P,, will make methods with low analytical imprecision less costly to control.
(Pf,=S%).
CONCLUDING REMARKS
Imprecision is important. It has been shown recently how data on biological variation may be generated and applied.'* Here, we have elaborated on the ways in which measurement imprecision affects test result variability, decision making using fixed limits and reference values, the significance of changes in serial results, the number of specimens to collect, the time which must be allowed between specimen collections and laboratory quality management.
We believe that efforts to improve imprecision are warranted for a number of analytes. We hope that clinical biochemists will consider more carefully the effect of imprecision on clinical decision making when they evaluate new reagent kit sets or methods, purchase new instruments, modify methods, and monitor their ongoing performance. We also hope that manufacturers will strive to provide us with techniques which meet our needs. The large data base on components of biological should assist in this process, as should use of the simple formulae documented here.
It may be that 'there is no evidence that patients or physicians are harmed by our present techniques as long as these meet existing standards'.' However, we believe that there is no evidence to the contrary either. It would be difficult to prove either point of view. We have demonstrated, however, that there are many reasons why 
